The present invention refers to the use of FasL antagonists, e.g. of humanizedantibodies directed against humanFas ligands (also named CD95L or Apo1L and hereinafter abbreviated as FasL)for the prevention and/or treatment of skindiseases associated with keratinocytes acantholysis, particularly for theprevention and/or treatment of pemphigus.